Manhattan Face and Eye Cosmetic and Orbital Surgery
New York, 10019, United States
NCT Number: NCT05945069
To demonstrate that DMSt + RF improves eye blink quality in subjects with dry eye disease
Looking for future studies?
Notify Me22 year and older
All sexes
Interventional
Not applicable
New York, 10019, United States
The purpose of the study is to demonstrate that a combination of DMSt and RF applied on the periocular skin below the lower eyelids improves eye blink quality in subjects with moderate to severe signs and symptoms of dry eye disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
binary (yes/no) variable, based on clinical estimation of the study investigator who will use a combination of two complementary tests (the lower lid distraction test and the snap-back test) to reach a yes/no decision.
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Biomicroscopy with the slit lamp; normal, mild, moderate, severe
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Subjectively assessed by the study investigator; normal, mildly impaired, moderately impaired, severely impaired
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Distances from the margins of the upper and lower lids to the central corneal reflex, in millimeters
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
15 meibomian glands along the lower lid (5 nasal + 5 central + 5 temporal) will be gently expressed with the dedicated expression forceps. Each gland will be scored 0 to 3, as follows: 0 = clear liquid meibum; 1 = cloudy liquid meibum; 2 = inspissated meibum; 3 = blocked). The modified Meibomian Gland score will be evaluated as the sum of scores for these 15 glands. Hence, the minimal value is 0 (all 15 glands express a clear liquid meibum), and the maximal value is 45 (all 15 glands are blocked). A decrease in the modiified Meibomian Gland Score means that the functionality of meibomian glands improved, and that the condition of the patient improved.
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Symptoms will be self-evaluated with the Ocular Surface Disease Index questionnaire. Twelve (12) questions will be asked about visual difficulties experienced by the subject during the past week. Each question will be scored 0 (none of the time), 1 (some of the time), 2 (half of the time), 3 (most of the time) or 4 (all the time). The Ocular Surface Disease Index will be calculated as the sum of scores times 25, divided by the number of questions answered. An increase in the Ocular Surface Disease Index means that the symptoms are reduced and that the condition of the patient improved.
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Measured with an esthesiometer; device settings: 1 to 6
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Blinks per minute during a video-watching task
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
full, or maximal vertical height of the palpebral fissure measured in mm
Time frame: 7 weeks after baseline (4 weeks after the 4th treatment)
Time between full blink and first appearance of a break in a fluorescein-stained eye
Time frame: Throughout the study and up to 7 weeks after baseline (4 weeks after the 4th treatment)
Incidence and type of adverse events
Time frame: At baseline, at 1 week after baseline (immediately before the second treatment), at 2 weeks after baseline (immediately before the third treatment), at 3 weeks after baseline (immediately before the fourth treatment) and at 7 weeks after baseline
Best-corrected visual acuity, using an ETDRS chart (20/20, 20/25, 20/32,20/40,20/50,20/63, 20/80, 20/100, 20/200, 20/400, where 20/20 is considered perfect vision and 20/400 is considered legal blindness)
Time frame: Immediately after a treatment session
Pain.discomfort will be self-reported with a visual analog scale (0 to 100), with 0 representing no pain/discomfort and 100 representing intolerable pain/discomfort. A decrease in this visual analog score represents an improvement in the perception of pain/discomfort.
Lumenis Be Ltd.
Industry
Feasibility of Dynamic Muscle Stimulation (DMSt) Combined with Radiofrequency (RF) for Improving Blink Quality in Subjects with Dry Eye Disease (DED)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04235803
Blepharoptosis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
San Francisco, California, United States
View Trial DetailsNCT06279143
BCC, BCC - Basal Cell Carcinoma
Vejle, Region of Southern Danmark, Denmark
View Trial DetailsNCT04149210
Eye Diseases, Eyelid Diseases
Addis Ababa, Ethiopia
View Trial DetailsNCT04898933
Eye Diseases, Eyelid Diseases
Abu Dhabi, United Arab Emirates
View Trial Details